Key clinical point: Onabotulinumtoxin A (OnabotA) may decrease migraine days by 50% or more.
Major finding: Of 112 patients with chronic migraine (100 female), 96 responded positively to OnabotA, resulting in decreased migraine days by at least 50%. Having a dependent personality trait was linked to treatment nonresponse.
Study details: This was a case-control observational study of chronic migraine patients that received two or more treatment cycles of OnabotA.
Disclosures: None.
Citation: Gonzalez-Martinez A, et al. Headache. 2019 Nov 6. doi: 10.1111/head.13693. [Epub ahead of print].